Impact of New Mpox Variant
Toronto has confirmed two travel-related cases of a new mpox variant, Clade Ib, which is raising health concerns in the region. This variant is linked to outbreaks in Central and Eastern Africa and is considered more severe than the previously reported Clade 2b.
As of the end of 2025, a total of 155 mpox cases had been confirmed in Toronto, highlighting the ongoing challenges posed by this virus. Symptoms of mpox include fever, chills, headache, muscle aches, fatigue, and rash, which can significantly impact those infected.
Toronto Public Health has stated that treatment guidance for mpox remains unchanged despite the emergence of this new variant. The mpox vaccine is available for eligible residents through clinics and community partners, and it is free, accessible with or without a health card.
Individuals who have received two doses of the mpox vaccine do not require additional vaccinations, providing some reassurance to those who have already been vaccinated. The virus can be transmitted through close, intimate, or sexual contact with an infected person, emphasizing the importance of awareness and preventive measures.
Current risk appears contained, but headlines can shift sentiment fast, indicating that public vigilance remains crucial. Health officials are monitoring the situation closely to ensure that any potential spread is addressed promptly.
While the situation is being managed, the emergence of Clade Ib raises questions about the future trajectory of mpox cases in Toronto and beyond. Further developments are expected as health authorities continue to assess the impact of this new variant.